Publication:
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics

dc.contributor.authorChittasupho C.
dc.contributor.authorSiahaan T.J.
dc.contributor.authorVines C.M.
dc.contributor.authorBerkland C.
dc.date.accessioned2021-04-05T03:35:14Z
dc.date.available2021-04-05T03:35:14Z
dc.date.issued2011
dc.date.issuedBE2554
dc.description.abstractProteins participating in immunological signaling have emerged as important targets for controlling the immune response. A multitude of receptor-ligand pairs that regulate signaling pathways of the immune response have been identified. In the complex milieu of immune signaling, therapeutic agents targeting mediators of cellular signaling often either activate an inflammatory immune response or induce tolerance. This review is primarily focused on therapeutics that inhibit the inflammatory immune response by targeting membrane-bound proteins regulating costimulation or mediating immune-cell adhesion. Many of these signals participate in larger, organized structures such as the immunological synapse. Receptor clustering and arrangement into organized structures is also reviewed and emerging trends implicating a potential role for multivalent therapeutics is posited. © 2011 Future Science Ltd.
dc.format.mimetypeapplication/pdf
dc.identifier.citationTherapeutic Delivery. Vol 2, No.7 (2011), p.873-889
dc.identifier.doi10.4155/tde.11.60
dc.identifier.issn20415990
dc.identifier.other2-s2.0-79961177838
dc.identifier.urihttps://hdl.handle.net/20.500.14740/7302
dc.rights.holderScopus
dc.subject.otherAbatacept
dc.subject.otherAdalimumab
dc.subject.otherAutoantibody
dc.subject.otherB7 antigen
dc.subject.otherBelatacept
dc.subject.otherCD28 antigen
dc.subject.otherCholinergic receptor
dc.subject.otherCorticosteroid derivative
dc.subject.otherCytokine
dc.subject.otherCytotoxic agent
dc.subject.otherCytotoxic T lymphocyte antigen 4
dc.subject.otherDacetuzumab
dc.subject.otherEfalizumab
dc.subject.otherEtanercept
dc.subject.otherGaliximab
dc.subject.otherImmunoglobulin
dc.subject.otherInfliximab
dc.subject.otherIntercellular adhesion molecule 1
dc.subject.otherIntercellular adhesion molecule 1 antibody
dc.subject.otherIpilimumab
dc.subject.otherLymphocyte function associated antigen 1
dc.subject.otherMajor histocompatibility antigen class 2
dc.subject.otherMembrane protein
dc.subject.otherMethotrexate
dc.subject.otherNatalizumab
dc.subject.otherProgrammed death 1 receptor
dc.subject.otherRituximab
dc.subject.otherThyrotropin receptor
dc.subject.otherTicilimumab
dc.subject.otherUnindexed drug
dc.subject.otherAntigen presenting cell
dc.subject.otherAutoimmune disease
dc.subject.otherAutoimmunity
dc.subject.otherB cell lymphoma
dc.subject.otherBrain infection
dc.subject.otherBrain ischemia
dc.subject.otherCell adhesion
dc.subject.otherCellular immunity
dc.subject.otherChronic lymphatic leukemia
dc.subject.otherCrohn disease
dc.subject.otherCytokine production
dc.subject.otherDrug protein binding
dc.subject.otherDrug receptor binding
dc.subject.otherDrug targeting
dc.subject.otherDrug withdrawal
dc.subject.otherHuman
dc.subject.otherImmunological synapse
dc.subject.otherImmunoregulation
dc.subject.otherImmunostimulation
dc.subject.otherLymphocyte proliferation
dc.subject.otherMelanoma
dc.subject.otherMultiple myeloma
dc.subject.otherMultiple sclerosis
dc.subject.otherNonhodgkin lymphoma
dc.subject.otherNonhuman
dc.subject.otherPhase 1 clinical trial (topic)
dc.subject.otherPhase 2 clinical trial (topic)
dc.subject.otherPhase 3 clinical trial (topic)
dc.subject.otherPriority journal
dc.subject.otherProgressive multifocal leukoencephalopathy
dc.subject.otherPsoriasis
dc.subject.otherReview
dc.subject.otherRheumatoid arthritis
dc.subject.otherSignal transduction
dc.subject.otherT lymphocyte activation
dc.subject.otherAnimals
dc.subject.otherAutoimmune Diseases
dc.subject.otherCell Adhesion
dc.subject.otherDrug Delivery Systems
dc.subject.otherHumans
dc.subject.otherImmune Tolerance
dc.subject.otherImmunological Synapses
dc.subject.otherInflammation
dc.subject.otherProteins
dc.subject.otherSignal Transduction
dc.titleAutoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics
dc.typeReview
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-79961177838&doi=10.4155%2ftde.11.60&partnerID=40&md5=34201a5607326ab185a08e4094899c9d

Files